1. Immunmodulatorische Stufentherapie der Multiplen Sklerose:
1. Ergänzung: Dezember 2000. Nervenarzt 2001;72:150-7.
2. Rieckmann P, Toyka KV. Immunmodulatorische Stufentherapie
der Multiplen Sklerose: Neue Aspekte und praktische
Umsetzung: März 2002. Nervenarzt 2002;73:556-63.
3. MS Therapie Konsensus Gruppe. Immunmodulatorische Stufentherapie
der Multiplen Sklerose. Nervenarzt 1999;70:371-86.
4. National Institute for Clinical Excellence. Multiple Sclerosis.
Management of multiple sclerosis in primary and secondary
care. Clinical Guideline 8. www.nice.org.uk . 2003.
5. Goodin DS, Frohman EM, Garmany GP, Jr., Halper J, Likosky
WH, Lublin FD et al. Disease modifying therapies in multiple
sclerosis: report of the Therapeutics and Technology
Assessment Subcommittee of the American Academy of
Neurology and the MS Council for Clinical Practice Guidelines.
Neurology 2002;58:169-78.
6. O’Connor P. Haematological abnormalities related to interferon-
ß 1A therapy. Mult.Scler. 2002;S89.
7. Ebers G. Natural history of MS. In: Compston A, Ebers G,
Lassmann, McDonald WI, Matthewes, Wekerle. McAlpine’s
Multiple Sclerosis, 3rd edition ed. London: Churchill Livinston,
1998.
8. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors
and progression of irreversible disability in multiple
sclerosis: an amnesic process. Brain 2003;126:770-82.
9. Nelson LM, Franklin GM, Hamman RF, Boteler DL, Baum
HM, Burks JS. Referral bias in multiple sclerosis research.
J.Clin.Epidemiol. 1988;41:187-92.
10. Lublin FD, Reingold SC. Defining the clinical course of multiple
sclerosis: results of an international survey. National Multiple
Sclerosis Society (USA) Advisory Committee on Clinical
Trials of New Agents in Multiple Sclerosis. Neurology
1996;46:907-11.
11. Richards RG, Sampson FC, Beard SM, Tappenden P. A
review of the natural history and epidemiology of multiple
sclerosis: implications for resource allocation and health economic
models. Health Technol.Assess. 2002;6:1-73.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis:
an expanded disability status scale (EDSS). Neurology
1983;33:1444-52.
13. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS,
Petkau J et al. Development of a multiple sclerosis functional
composite as a clinical trial outcome measure.
Brain 1999;122: 871-82.
14. Hoogervorst EL, Eikelenboom MJ, Uitdehaag BM, Polman
CH. One year changes in disability in multiple sclerosis:
neurological examination compared with patient self report.
J.Neurol.Neurosurg.Psychiatry 2003;74:439-42.
15. Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson
AJ, Miller DH. A longitudinal study of abnormalities on MRI
and disability from multiple sclerosis.
N.Engl.J.Med. 2002;346:158-64.
16. TNF neutralization in MS: results of a randomized, placebocontrolled
multicenter study. The Lenercept Multiple Sclerosis
Study Group and The University of British Columbia
MS/MRI Analysis Group. Neurology 1999;53:457-65.
17. Sormani MP, Bruzzi P, Beckmann K, Wagner K, Miller DH,
Kappos L et al. MRI metrics as surrogate endpoints for EDSS
progression in SPMS patients treated with IFN beta-1b.
Neurology 2003;60:1462-6.
18. Wiendl H, Neuhaus O, Kappos L, Hohlfeld R. Aktuelle
Übersicht zu fehlgeschlagenen und abgebrochenen Therapiestudien.
Nervenarzt 2000;71:597-610.
19. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert
JR, Salazar AM et al. Intramuscular interferon beta-1a for
disease progression in relapsing multiple sclerosis. The Multiple
Sclerosis Collaborative Research Group (MSCRG).
Ann.Neurol. 1996;39:285-94.
20. Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D’Amico
R et al. Interferon in relapsing-remitting multiple sclerosis.
Cochrane.Database.Syst.Rev. 2001.
21. Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G,
Midgard R et al. Corticosteroids or ACTH for acute exacerbations
in multiple sclerosis. Cochrane.Database.Syst.Rev. 2000.
22. Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy
JH, Lucchinetti CF, Dodick DW et al. A randomized trial of
plasma exchange in acute central nervous system inflammatory
demyelinating disease. Ann.Neurol. 1999;46:878-86.
23. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV,
Propper RD et al. Intensive immunosuppression in progressive
multiple sclerosis. A randomized, three-arm study of
high-dose intravenous cyclophosphamide, plasma exchange,
and ACTH. N.Engl.J.Med. 1983;308:173-80.
24. The Canadian cooperative trial of cyclophosphamide and
plasma exchange in progressive multiple sclerosis. The Canadian
Cooperative Multiple Sclerosis Study Group.
Lancet 1991;337:441-6.
25. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle
CM, Murray TJ et al. Intramuscular interferon beta-1a therapy
initiated during a first demyelinating event in multiple
sclerosis. CHAMPS Study Group.
N.Engl.J.Med. 2000;343:898-904.
26. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez
O et al. Effect of early interferon treatment on conversion to
definite multiple sclerosis: a randomised study.
Lancet 2001;357:1576-82.
27. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis
FA, Ebers GC et al. New diagnostic criteria for multiple
sclerosis: guidelines for research protocols.
Ann.Neurol. 1983;13:227-31.
28. McDonald WI, Compston A, Edan G, Goodkin D, Hartung
HP, Lublin FD et al. Recommended diagnostic criteria for
multiple sclerosis: guidelines from the International Panel on
the diagnosis of multiple sclerosis. Ann.Neurol. 2001;50:121-7.
29. MRI predictors of early conversion to clinically definite MS in
the CHAMPS placebo group. Neurology 2002;59:998-1005.
30. Barkhof F, Rocca M, Francis G, Van Waesberghe JH, Uitdehaag
BM, Hommes OR et al. Validation of diagnostic
magnetic resonance imaging criteria for multiple sclerosis
and response to interferon beta1a. Ann.Neurol. 2003;53:718-24.
31. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman
CH et al. Comparison of MRI criteria at first presentation
to predict conversion to clinically definite multiple sclerosis.
Brain 1997;120 ( Pt 11):2059-69.
32. Interferon beta-1b in the treatment of multiple sclerosis: final
outcome of the randomized controlled trial. The IFNB Multiple
Sclerosis Study Group and The University of British
Columbia MS/MRI Analysis Group. Neurology 1995;45:1277-85.
33. Kappos, L. Long term tolerability to interferon beta-1a in
relapsing-remitting MS: 6-year safety follow-up of the PRISM
study. Joint ECTRIMS/ACTRIMS meeting 18.-22.9.02. 2002.
Baltimore, US.
34. Knobler RL, Greenstein JI, Johnson KP, Lublin FD, Panitch
HS, Conway K et al. Systemic recombinant human interferon-
beta treatment of relapsing-remitting multiple sclerosis:
pilot study analysis and six-year follow-up.
J.Interferon Res. 1993;13:333-40.
35. Interferon beta-1b is effective in relapsing-remitting multiple
sclerosis. I. Clinical results of a multicenter, randomized,
double-blind, placebo-controlled trial. The IFNB Multiple
Sclerosis Study Group. Neurology 1993;43:655-61.
36. Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R,
Ferrio MF et al. Chronic systemic high-dose recombinant
interferon alfa-2a reduces exacerbation rate, MRI signs of
disease activity, and lymphocyte interferon gamma production
in relapsing-remitting multiple sclerosis.
Neurology 1994;44:406-13.
37. Randomised double-blind placebo-controlled study of interferon
beta-1a in relapsing/remitting multiple sclerosis.
PRISMS (Prevention of Relapses and Disability by Interferon
beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Lancet 1998;352:1498-504.
38. Myhr KM, Riise T, Green Lilleas FE, Beiske TG, Celius EG,
Edland A et al. Interferon-alpha2a reduces MRI disease
activity in relapsing-remitting multiple sclerosis. Norwegian
Study Group on Interferon-alpha in Multiple Sclerosis.
Neurology 1999;52:1049-56.
39. Evidence of interferon beta-1a dose response in relapsingremitting
MS: the OWIMS Study. The Once Weekly Interferon
for MS Study Group. Neurology 1999;53:679-86.
40. Francis GS, Grumser Y, Alteri E, Micaleff A, O’Brien F,
Alsop J et al. Hepatic reactions during treatment of multiple
sclerosis with interferon-beta-1a: incidence and clinical significance.
Drug Saf 2003;26:815-27.
41. Tremlett HL, Yoshida EM, Oger J. Liver injury associated
with the beta-interferons for MS: a comparison between the
three products. Neurology 2004;62:628-31.
42. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi
A et al. Every-other-day interferon beta-1b versus once-weekly
interferon beta-1a for multiple sclerosis: results of a 2-year
prospective randomised multicentre study (INCOMIN).
Lancet 2002;359:1453-60.
43. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK,
O’Connor P et al. Randomized, comparative study of interferon
beta-1a treatment regimens in MS: The EVIDENCE
Trial. Neurology 2002;59:1496-506.
44. Walther EU, Dang T, Hartung HP, Hohlfeld R. Bildung von
neutralisierenden Antikörpern unter Therapie der multiplen
Sklerose mit Interferon beta-1b: Praktisches Vorgehen bei
Verdacht auf Therapieversagen. Nervenarzt 1997;68:935-9.
45. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen
JL, Jensen K et al. Antibodies to IFN-beta: the Danish
National IFN-beta Project. Neurology 2003;61:S27-S28.
46. Pachner AR. Anti-IFNß antibodies in IFNß-treated MS patients:
Summary. Neurology 2003;61:1-5.
47. Bertolotto A. Neutralizing antibodies to interferon beta: implications
for the management of multiple sclerosis.
Curr.Opin.Neurol. 2004;17:241-6.
48. Maurer M, Gold R, Toyka KV, Rieckmann P. Treatment of
relapsing-remitting multiple sclerosis with recombinant interferon-
beta preparations. Nervenarzt 2001;72:108-16.
49. Salama HH, Hong J, Zang YC, El Mongui A, Zhang J.
Blocking effects of serum reactive antibodies induced by glatiramer
acetate treatment in multiple sclerosis.
Brain 2003;126:2638-47.
50. Feinstein A, O’Connor P, Feinstein K. Multiple sclerosis,
interferon beta-1b and depression A prospective investigation.
J.Neurol. 2002;249:815-20.
51. Borras C, Rio J, Porcel J, Barrios M, Tintore M, Montalban
X. Emotional state of patients with relapsing-remitting MS
treated with interferon beta-1b. Neurology 1999;52:1636-9.
52. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H,
Drexler E et al. A pilot trial of Cop 1 in exacerbating-remitting
multiple sclerosis. N.Engl.J.Med. 1987;317:408-14.
53. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J,
Lisak RP et al. Copolymer 1 reduces relapse rate and improves
disability in relapsing-remitting multiple sclerosis: results
of a phase III multicenter, double-blind placebo-controlled
trial. The Copolymer 1 Multiple Sclerosis Study Group.
Neurology 1995;45:1268-76.
54. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter,
double-blind, randomized, placebo-controlled study of
the effects of glatiramer acetate on magnetic resonance imaging—
measured disease activity and burden in patients with
relapsing multiple sclerosis. European/Canadian Glatiramer
Acetate Study Group. Ann.Neurol. 2001;49:290-7.
55. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate
for multiple sclerosis.
Cochrane.Database.Syst.Rev. 2004;CD004678.
56. Johnson KP, Brooks BR, Ford CC, Goodman AD, Lisak RP,
Myers LW et al. Glatiramer acetate (Copaxone): comparison
of continuous versus delayed therapy in a six-year organized
multiple sclerosis trial. Mult.Scler. 2003;9:585-91.
57. Comi G, Moiola L. Glatiramer acetate.
Neurologia 2002;17:244-58.
58. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA,
Lisak RP. A prospective, open-label treatment trial to compare
the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron),
and glatiramer acetate (Copaxone) on the relapse rate in
relapsing—remitting multiple sclerosis: results after 18
months of therapy. Mult.Scler. 2001;7:349-53.
59. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA,
McPherson K et al. Overview of azathioprine treatment in
multiple sclerosis. Lancet 1991;338:1051-5.
60. Mertin J, Rudge P, Kremer M, Healey MJ, Knight SC,
Compston A et al. Double-blind controlled trial of immunosuppression
in the treatment of multiple sclerosis: final
report. Lancet 1982;2:351-4.
61. Milanese C, La Mantia L, Salmaggi A, Campi A, Bortolami
C, Tajoli L et al. Double blind controlled randomized study on
azathioprine efficacy in multiple sclerosis. Preliminary results.
Ital.J.Neurol.Sci. 1988;9:53-7.
62. Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte
WW, Syndulko K et al. A placebo-controlled, randomized,
double-masked, variable dosage, clinical trial of azathioprine
with and without methylprednisolone in multiple sclerosis.
Neurology 1989;39:1018-26.
63. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty
WW. The efficacy of azathioprine in relapsing-remitting multiple
sclerosis. Neurology 1991;41:20-5.
64. Palace J, Rothwell P. New treatments and azathioprine in
multiple sclerosis. Lancet 1997;350:261.
65. Cavazzuti M, Merelli E, Tassone G, Mavilla L. Lesion load
quantification in serial MR of early relapsing multiple sclerosis
patients in azathioprine treatment. A retrospective study.
Eur.Neurol. 1997;38:284-90.
66. Milanese C, La Mantia L, Salmaggi A, Caputo D. Azathioprine
and interferon beta-1b treatment in relapsing-remitting
multiple sclerosis. J.Neurol.Neurosurg.Psychiatry 2001;70:413-4.
67. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y,
Gornish M et al. Intravenous immunoglobulin treatment in
multiple sclerosis. Effect on relapses.
Neurology 1998;50:398-402.
68. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G,
Mamoli B. Randomised placebo-controlled trial of monthly
intravenous immunoglobulin therapy in relapsingremitting
multiple sclerosis. Austrian Immunoglobulin in Multiple
Sclerosis Study Group. Lancet 1997;349:589-93.
69. Gray O, McDonnell GV, Forbes RB. Intravenous immunoglobulins
for multiple sclerosis.
Cochrane.Database.Syst.Rev. 2003;CD002936.
70. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg
M, Ravnborg M et al. Intravenous immunoglobulin
G reduces MRI activity in relapsing multiple sclerosis.
Neurology 1998;50:1273-81.
71. Teksam M, Tali T, Kocer B, Isik S. Qualitative and quantitative
volumetric evaluation of the efficacy of intravenous immunoglobulin
in multiple sclerosis: preliminary report.
Neuroradiology 2000;42:885-9.
72. van Engelen BG, Hommes OR, Pinckers A, Cruysberg JR,
Barkhof F, Rodriguez M. Improved vision after intravenous
immunoglobulin in stable demyelinating optic neuritis.
Ann.Neurol. 1992;32:834-5.
73. Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S.
Placebo controlled pilot trial to study the remyelinating potential
of intravenous immunoglobulins in multiple sclerosis.
J.Neurol.Neurosurg.Psychiatry 2000;68:89-92.
74. Noseworthy JH, O’Brien PC, Petterson TM, Weis J, Stevens
L, Peterson WK et al. A randomized trial of intravenous
immunoglobulin in inflammatory demyelinating optic neuritis.
Neurology 2001;56:1514-22.
75. Lewanska M, Siger-Zajdel M, Selmaj K. No difference in
efficacy of two different doses of intravenous immunoglobulins
in MS: clinical and MRI assessment.
Eur.J.Neurol. 2002;9:565-72.
76. Bates D, Cartlidge NE, French JM, Jackson MJ, Nightingale
S, Shaw DA et al. A double-blind controlled trial of long
chain n-3 polyunsaturated fatty acids in the treatment of multiple
sclerosis. J.Neurol.Neurosurg.Psychiatry 1989;52:18-22.
77. Millar JH, Zilkha KJ, Langman MJ, Wright HP, Smith AD,
Belin J et al. Double-blind trial of linoleate supplementation
of the diet in multiple sclerosis. Br.Med.J. 1973;1:765-8.
78. Paty DW. Double-blind trial of linoleic acid in multiple sclerosis.
Arch.Neurol. 1983;40:693-4.
79. Bates D, Fawcett PR, Shaw DA, Weightman D. Polyunsaturated
fatty acids in treatment of acute remitting multiple
sclerosis. Br.Med.J. 1978;2:1390-1.
80. Dworkin RH, Bates D, Millar JH, Paty DW. Linoleic acid and
multiple sclerosis: a reanalysis of three double-blind trials.
Neurology 1984;34:1441-5.
81. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M,
Pozzi-Mucelli RS et al. Effects of IV methylprednisolone on
brain atrophy in relapsing-remitting MS.
Neurology 2001;57:1239-47.
82. Millefiorini E, Gasperini C, Pozzilli C, D’Andrea F, Bastianello
S, Trojano M et al. Randomized placebo-controlled trial
of mitoxantrone in relapsing-remitting multiple sclerosis: 24-
month clinical and MRI outcome. J.Neurol. 1997;244:153-9.
83. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O,
Lubetzki C et al. Therapeutic effect of mitoxantrone combined
with methylprednisolone in multiple sclerosis: a randomised
multicentre study of active disease using MRI and clinical
criteria. J.Neurol.Neurosurg.Psychiatry 1997;62:112-8.
84. Lus G, Romano F, Scuotto A, Accardo C, Cotrufo R. Azathioprine
and interferon beta(1a) in relapsing-remitting multiple
sclerosis patients: increasing efficacy of combined treatment.
Eur.Neurol. 2004;51:15-20.
85. Placebo-controlled multicentre randomised trial of interferon
beta-1b in treatment of secondary progressive multiple
sclerosis. European Study Group on interferon beta-1b in
secondary progressive MS. Lancet 1998;352:1491-7.
86. Goodkin, D. The North Amercian study of IFNß in SPMS.
2001. Schering Research and Development.
87. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann
K, Dahlke F. Final analysis of the European multicenter trial
on IFNbeta-1b in secondary-progressive MS.
Neurology 2001;57:1969-75.
88. Randomized controlled trial of interferon- beta-1a in secondary
progressive MS: Clinical results.
Neurology 2001;56:1496-504.
89. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich
FR, Kooijmans MF et al. Benefit of interferon beta-1a
on MSFC progression in secondary progressive MS.
Neurology 2002;59:679-87.
90. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A,
Morrissey SP et al. Mitoxantrone in progressive multiple
sclerosis: a placebo-controlled, double-blind, randomised,
multicentre trial. Lancet 2002;360:2018-25.
91. Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S,
Hartung HP et al. Cardiac adverse effects associated with
mitoxantrone (Novantrone) therapy in patients with MS.
Neurology 2002;59:909-13.
92. Chaplain G, Milan C, Sgro C, Carli PM, Bonithon-Kopp C.
Increased risk of acute leukemia after adjuvant chemotherapy
for breast cancer: a population-based study.
J.Clin.Oncol. 2000;18:2836-42.
93. Ghalie RG, Mauch E, Edan G, Hartung HP, Gonsette RE,
Eisenmann S et al. A study of therapy-related acute leukaemia
after mitoxantrone therapy for multiple sclerosis.
Mult.Scler. 2002;8:441-5.
94. Double-masked trial of azathioprine in multiple sclerosis. British
and Dutch Multiple Sclerosis Azathioprine Trial Group.
Lancet 1988;2:179-83.
95. Ghezzi A. Clinical controlled randomised trial of azathioprine
in multiple sclerosis. In: Gonsette RE, Delmotte. Recent
advantages in multiple sclerosis. Amsterdam: Elsevier, 1989.
96. Amato MP, Pracucci G, Ponziani G, Siracusa G, Fratiglioni
L, Amaducci L. Longterm
safety of azathioprine therapy in multiple sclerosis.
Neurology 1993;43:831-3.
97. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine
P, Aimard G. Risk of cancer from azathioprine therapy in multiple
sclerosis: a case-control study.
Neurology 1996;46:1607-12.
98. Polifka JE, Friedman JM. Teratogen update: azathioprine
and 6-mercaptopurine. Teratology 2002;65:240-61.
99. Fernandez O, Guerrero M, Mayorga C, Munoz L, Lean A,
Luque G et al. Combination therapy with interferon beta-1b
and azathioprine in secondary progressive multiple sclerosis.
A two-year pilot study. J.Neurol. 2002;249:1058-62.
100. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM,
LaPierre Y et al. Intermittent cyclophosphamide pulse therapy
in progressive multiple sclerosis: final report of the Northeast
Cooperative Multiple Sclerosis Treatment Group.
Neurology 1993;43:910-8.
101. Currier RD, Haerer AF, Meydrech EF. Low dose oral
methotrexate treatment of multiple sclerosis: a pilot study.
J.Neurol.Neurosurg.Psychiatry 1993;56:1217-8.
102. Goodkin DE, Rudick RA, VanderBrug MS, Daughtry MM,
Schwetz KM, Fischer J et al. Low-dose (7.5 mg) oral
methotrexate reduces the rate of progression in chronic progressive
multiple sclerosis. Ann.Neurol. 1995;37:30-40.
103. Beyeler C. Methotrexatbehandlung der rheumatoiden Arthritis.
Schweiz.Med.Wochenschr. 1996;126:703-12.
104. Goodkin DE, Kinkel RP, Weinstock-Guttman B, Vander-
Brug-Medendorp S, Secic M, Gogol D et al. A phase II
study of i.v. methylprednisolone in secondary-progressive
multiple sclerosis. Neurology 1998;51:239-45.
105. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler
E. Cladribine in treatment of chronic progressive multiple
sclerosis. Lancet 1994;344:9-13.
106. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A
double-blind, placebocontrolled,
randomized trial of cladribine in relapsing-remitting
multiple sclerosis. Proc.Assoc.Am.Physicians 1999;111:35-44.
107. Rice GP, Filippi M, Comi G. Cladribine and progressive MS:
clinical and MRI outcomes of a multicenter controlled trial.
Cladribine MRI Study Group. Neurology 2000;54:1145-55.
108. Rudge P, Koetsier JC, Mertin J, Mispelblom Beyer JO, Van
Walbeek HK, Clifford JR et al. Randomised double blind
controlled trial of cyclosporin in multiple sclerosis.
J.Neurol.Neurosurg.Psychiatry 1989;52:559-65.
109. Efficacy and toxicity of cyclosporine in chronic progressive
multiple sclerosis: a randomized, double-blinded, placebocontrolled
clinical trial. The Multiple Sclerosis Study Group.
Ann.Neurol. 1990;27:591-605.
110. Leary SM, Thompson AJ. Interferon beta-1a in primary progressive
multiple sclerosis. J.Neurol.Sci. 2003;206:215-6.
111. Montalban X. Effects of IFNß in PPMS.
Mult.Scler. 2003;9:S18.
112. Wolinsky JS PLSZBKSLD. Primary progressive MS: what
can we learn from the PROMISE trial? Mult.Scler. 2003;9:38.
113. Bielekova B, Richert N, Howard T, Blevins G, Markovic-
Plese S, McCartin J et al. Humanized anti-CD25 (daclizumab)
inhibits disease activity in multiple sclerosis patients failing to
respond to interferon {beta}.
Proc.Natl.Acad.Sci.U.S.A 2004;101:8705-8.
114. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice
GP, Libonati MA et al. A controlled trial of natalizumab for
relapsing multiple sclerosis. N.Engl.J.Med. 2003;348:15-23.
115. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-
Plese S et al. Oral simvastatin treatment in relapsing-remitting
multiple sclerosis. Lancet 2004;363:1607-8.
116. Munger KL, Zhang SM, O’Reilly E, Hernan MA, Olek MJ,
Willett WC et al. Vitamin D intake and incidence of multiple
sclerosis. Neurology 2004;62:60-5.
117. Bennett M, Heard R. Treatment of multiple sclerosis with
hyperbaric oxygen therapy.
Undersea Hyperb.Med. 2001;28:117-22.
118. Barnes MP, Bates D, Cartlidge NE, French JM, Shaw DA.
Hyperbaric oxygen and multiple sclerosis: final results of a
placebo-controlled, double-blind trial.
J.Neurol.Neurosurg.Psychiatry 1987;50:1402-6.
119. Huntley A, Ernst E. Complementary and alternative therapies
for treating multiple sclerosis symptoms: a systematic
review. Complement Ther.Med. 2000;8:97-105.
120. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al.
Cannabinoids for treatment of spasticity and other symptoms
related to multiple sclerosis (CAMS study): multicentre randomised
placebo-controlled trial. Lancet 2003;362:1517-26.
121. Oken BS, Kishiyama S, Zajdel D, Bourdette D, Carlsen J,
Haas M et al. Randomized controlled trial of yoga and exercise
in multiple sclerosis. Neurology 2004;62:2058-64.
122. O’Connor AM, Rostom A, Fiset V, Tetroe J, Entwistle V,
Llewellyn-Thomas H et al. Decision aids for patients facing
health treatment or screening decisions: systematic review.
Br.Med.J. 1999;319:731-4.
123. Coulter A, Entwistle V, Gilbert D. Sharing decisions with
patients: is the information good enough?
Br.Med.J.1999;318:318-22.
124. Holmes-Rovner M, Llewellyn-Thomas H, Entwistle V,
Coulter A, O’Connor A, Rovner DR. Patient choice modules
for summaries of clinical effectiveness: a proposal. Br.Med.J.
2001;322:664-7.
125. Edwards A, Elwyn G, Mulley A. Explaining risks: turning
numerical data into meaningful pictures. Br.Med.J. 2002;
324:827-30.